Scientists / Our Scientists

Xin Ye

Senior Principal Scientist, Discovery Oncology, Research Biology

Postdoc Mentor

Years at Genentech

Awards & Honors

I obtained my PhD from Johns Hopkins University School of Medicine, studying Frizzled signaling in retinal angiogenesis and established Norrin/Frizzled4 pathway as a key regulator of retinal endothelial cell development with Dr. Jeremy Nathans. I then trained with Dr. Bob Weinberg as a Helen Hey Whitney Postdoctoral Fellow at Whitehead Institute/MIT, where my work uncovered distinct transcriptional programs that control stemness in normal mammary gland versus in breast cancer.

I joined the Department of Discovery Oncology as a group leader in 2017. My group is interested in developing new technologies and methods to dissect pre-existing and adaptive programs associated with responses versus resistance to targeted therapies. We hope such knowledge will reveal new targets and facilitate rational designs of drug combinations.

Postdoctoral Mentor

Postdocs bring fresh ideas to our research community and the postdoc program provides groups like mine a valuable opportunity to pursue important research questions related to our drug targets. I am honored to be part of this top-class program and look forward to mentoring future generations of scientists and growing my science with them.

Featured Publication

CRISPR activation screens identify the SWI/SNF ATPases as suppressors of ferroptosis.

Cell Reports; 2024.

Kamakoti P. Bhat, Jinchu Vijay, Caroline K. Vilas, Jyoti Asundi, Jun Zou, Ted Lau, Xiaoyu Cai, Musaddeque Ahmed, Michal Kabza, Julie Weng, Jean-Philippe Fortin, Aaron Lun, Steffen Durinck, Marc Hafner, Michael R. Costa & Xin Ye.

View Abstract

Perivascular neurons instruct 3D vascular lattice formation via neurovascular contact.

Cell; 2024.

Kenichi Toma, Mengya Zhao, Shaobo Zhang, Fei Wang, Hannah K Graham, Jun Zou, Shweta Modgil, Wenhao H. Shang, Nicole Y. Tsai, Zhishun Cai, Liping Liu, Guiying Hong, Arnold R Kriegstein, Yang Hu, Jakob Körbelin, Ruobing Zhang, Yaping Joyce Liao, Tyson N. Kim, Xin Ye & Xin Duan.

View Abstract

Targeting the Hippo pathway in cancers via ubiquitination dependent TEAD degradation.

Elife; 2024

Trang H. Pham, Kanika Bajaj Pahuja, Thijs J. Hagenbeek, Jason Zbieg, Cameron L. Noland, Victoria C. Pham, Xiaosai Yao, Christopher M. Rose, Kristen Browder, Ho-June Lee, Mamie Yu, May Liang-Chu, Scott Martin, Erik Verschueren, Jason Li, Marta H. Kubala, Rina Fong, Maria Lorenzo, Paul Beroza, Peter Hsu, Sayantanee Paul, Elisia Villemure, Wendy Lee, Tommy K. Cheung, Saundra Clausen, Jennifer Lacap, Yuxin Liang, Jason Cheng, Steve Schmidt, Zora Modrusan, Michael Cohen, James Crawford, Heinrich Jasper, Alan Ashworth, Jennie R. Lill, Shiva Malek, Joachim Rudolph, Ingrid E. Wertz, Matthew T. Chang, Xin Ye & Anwesha Dey.

View Abstract

An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance.

Nature Cancer; 2023

hijs J. Hagenbeek, Jason R. Zbieg, Marc Hafner, Rana Mroue, Jennifer A. Lacap, Nicole M. Sodir, Cameron L. Noland, Shervin Afghani, Ayush Kishore, Kamakoti P. Bhat, Xiaosai Yao, Stephen Schmidt, Saundra Clausen, Micah Steffek, Wendy Lee, Paul Beroza, Scott Martin, Eva Lin, Rina Fong, Paola Di Lello, Marta H. Kubala, Michelle N.-Y. Yang, Jeffrey T. Lau, Emily Chan, Alfonso Arrazate, Le An, Elizabeth Levy, Maria N. Lorenzo, Ho-June Lee, Trang H. Pham, Zora Modrusan, Richard Zang, Yi-Chen Chen, Michal Kabza, Musaddeque Ahmed, Jason Li, Matthew T. Chang, Danilo Maddalo, Marie Evangelista, Xin Ye, James J. Crawford & Anwesha Dey

View Abstract

Identifying transcriptional programs underlying cancer drug response with TraCe-seq;

Nature Biotechnology; 2021

Chang, M.T., Shanahan, F., Nguyen, T.T.T., Staben, S.T., Gazzard, L., Yamazoe, S., Wertz, I.E., Piskol, R., Yang, A., Modrusan, Z., Haley, B., Evangelista, E., Malek, S., Foster, S.A., Ye, X.

View Abstract

Targeted therapies have demonstrated significant clinical benefits in many cancer patients. We believe that a deep understanding of the mechanisms underlying therapeutic responses versus resistance will spur the development of newer therapeutic approaches. We are particularly interested in dissecting the pre-existing and adaptive transcriptional programs that drive therapy resistance by leveraging and developing single cell and genomics approaches.

Whitehead Institute, MIT, Postdoctoral Fellow – 2017
The Johns Hopkins University School of Medicine, Ph.D. – 2010
Tsinghua University, Biological Sciences and Biotechnology, B.S. – 2004

Genentech Research and Innovation Fund – 2018, 2019
Cancer Prevention & Research Institute of Texas (CPRIT) Award (Declined) – 2016
Distinction in Teaching Award, Harvard University – 2016
NCI Pathway to Independence Award (K99) – 2015 - 2017
Helen Hay Whitney Postdoctoral Fellowship – 2010 - 2013
Damon Runyon Cancer Research Foundation Postdoctoral Research Fellowship Award (Declined) – 2010
The Martin and Carol Macht Award, Young Investigators’ Day Program, Johns Hopkins University School of Medicine – 2010
Tsinghua University Distinguished Scholarship – 2004

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Xin Ye

Senior Principal Scientist, Discovery Oncology, Research Biology

Featured Publication

CRISPR activation screens identify the SWI/SNF ATPases as suppressors of ferroptosis.

Perivascular neurons instruct 3D vascular lattice formation via neurovascular contact.

Targeting the Hippo pathway in cancers via ubiquitination dependent TEAD degradation.

An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance.

Identifying transcriptional programs underlying cancer drug response with TraCe-seq;